Glenmark Pharmaceuticals Receives EIR from U.S. FDA for Monroe Facility

Glenmark Pharmaceuticals Ltd, a research-led global pharmaceutical company, has announced that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (U.S. FDA) for its formulations manufacturing facility in Monroe, North Carolina, USA. The inspection was conducted from 09 June to 17 June 2025. This positive development will allow the company to restart commercial manufacturing at the site, which was previously under a Warning Letter since June 2023. Glenmark is a significant player in the pharmaceutical industry, with a presence in over 80 countries and 11 manufacturing facilities across four continents. The company is focused on therapeutic areas of respiratory, dermatology, and oncology.